Eileen M O’Reilly

Exciting to see these results out! Lots to build on - congratulations @ superb MSK pancreas team (no biases!) and complex insightful analyses led by @CentralParkWMD @MSKCancerCenter and as #ASCO23 winds down…. back to the real work of implementing all the learnings to practice!

🚨🚨🚨 RASOLUTE-302 Ph3 is POSITIVE "Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW! AMAZING news for patients with #PancreaticCancer The RAS Revolution is ON!! ir.revmed.com/news-releases/…

1) Finally out. I am really proud of this work, that shows the awesome power of cancer cell plasticity to adapt to any environment. Kudus to Alejandro Jimenez Sanchez and @scpersad ->

New in the April 1 issue from the Cancer Research special series: Transcriptomic Plasticity Is a Hallmark of Metastatic Pancreatic Cancer doi.org/10.1158/0008-5… @arnavmehta3 @centralparkwmd @EileenMOReilly @ciacobu @dana_peer #OpenAccess

AACR congratulates Kenneth M. Murphy, MD, PhD, recipient of the 2026 AACR-@CancerResearch Lloyd J. Old Award in Cancer Immunology. He will accept the award and deliver remarks on Tuesday, April 21, at 3 p.m. PT, during #AACR26 in San Diego. brnw.ch/21x1svW @washumedicine

Excited to join #DHAI2026. @GABOUALFA @MSKCancerCenter will be joining @Amir Lahav and team at @Digital Health & AI Innovation (DHAI) Summit take the stage and discuss precision medicine. Looking forward to connecting with clinicians, scientists, and AI experts shaping the future

We are immensely proud to honor Dr. Ribas, a deeply committed physician-scientist whose work has connected foundational scientific discovery with clinical innovation, leading to major breakthroughs in the treatment of a wide spectrum of cancers and saving countless lives.

Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants aacrjournals.org/cancerdiscover… Phase 1 is now open & enrolling at @nyulangone @Perlmutter_CC clinicaltrials.gov/study/NCT06917… @salmanpunekar @JSabari

Extrapulmonary neuroendocrine carcinoma (epNEC) is a highly lethal cancer and current therapy is very inadequate. Beyond first-line therapy with platinum/etoposide (PE), nothing reliably works well and survival is short. Even though epNEC is very different from SCLC (very different genomics), we keep treating with PE expecting good results. This retrospective study adds to the lit. FOLFIRINOX in patients with epNECs of GI origin, mostly second line, seems to have activity and is a regimen I often suggest upfront in patients with pancreatic or colorectal NECs, especially if non-small cell type. Keep also in mind that many colorectal NECs have a BRAF V600E mutation and should perhaps be treated with EC-FOLFOX/EC-FOLFIRI. onlinelibrary.wiley.com/doi/10.1111/jn…

New @MolecularCell paper from Chi Dang @Ludwig_Cancer The HIF-2 transcription factor mediates resistance to ferroptosis in #PancreaticCancer #bib30" target="_blank" rel="nofollow noopener">sciencedirect.com/science/articl… Elegant mechanistic study, however Belzutifan (HIF2 inhibitor) does not work in mitigating HIF2 in this cancer.

Congratulations to Dr. Charles Sawyers, an investigator at Memorial Sloan Kettering Cancer Center (MSK), on receiving the 13th annual Harrington Prize for Innovation in Medicine. Dr. Sawyers, who is Chair of Human Oncology and Pathogenesis Program at MSK and a Howard Hughes Medical Institute (HHMI) Investigator, was jointly awarded the prize with Dr. Arul Chinnaiyan, an investigator at the University of Michigan and the HHMI. The award recognizes their transformative discoveries that defined the molecular drivers of prostate cancer and pioneered precision therapies that have reshaped the diagnosis and treatment of prostate cancer worldwide. Together, Drs. Sawyers and Chinnaiyan have developed the contemporary framework for diagnosis and treatment of advanced prostate cancer and a basis for next generation therapies. The Harrington Prize for Innovation in Medicine recognizes their impact on improving outcomes in this deadly disease. Dr. Sawyers also holds the Marie-Josée and Henry R. Kravis Chair in Human Oncology and Pathogenesis at MSK. Learn more: bit.ly/41UnLyI

We congratulate the 2026 Class of Fellows of the AACR Academy. The newest AACR Fellows will be inducted during a special ceremony on Friday, April 17 at #AACR26. brnw.ch/21x1l03

This PhI/IIb trial #MORPHEUSPDAC tested #atezolizumab combos in advanced #pancsm All regimens showed #limited efficacy (ORR 0–16.7%) with manageable safety. We need better post-first-line treatments. #GIonc @susanebates @gbanna74 @PasRescigno doi.org/10.1093/oncolo…

Amazing work by @centralparkwmd, @EileenMOReilly, and colleagues. 🧬🫆💉

Dr. Deb Citrin is Scientific Director for Clinical Research at the NCI – the first rad onc to ever hold this role. Thank you, @DeborahCitrin for repping our specialty @theNCI!

A great win for @MayoClinic and our #Florida destination medical center — taking our #gastrointestinal #cancer @MayoCancerCare dream team to the next level @VamsiVelcheti linkedin.com/posts/vamsi-ve…

Yesterday we celebrated our 16th annual Paul Calabresi memorial lectureship @YaleCancer @SmilowCancer @YaleMedicine Honored to have Dr. Robert Winn @VCUMassey @FoxChaseCancer @WinnAwards visiting. What a wonderful few days with our Yale Winn Scholars, Center Faculty, Students and the Calabresi Family! @PaulBGoldberg @Calabre04804429 @DrEricWiner Great lecture: our time is now to make change says RW!

@Aiims1742 @NatureMedicine @EileenMOReilly This adenosine-NR4A axis feels like unlocking a new level in PDAC immunotherapy. Spatial scarcity of activated T cells near high NR4A regions illustrates the immunosuppressive gradient challenge.

In a @NEJM editorial, Department of Medicine Chair @DebSchrag reflected on 30 years of incredible progress in #coloncancer treatment and identified opportunities to harness insights from biomarker testing to customize therapies that reduce side effects. @MSKCancerCenter 📖 bit.ly/4clZWoH

New @NatureMedicine paper from @EileenMOReilly Quemliclustat (CD73 antagonist) and chemotherapy with or without zimberelimab (anti-PD1) in metastatic #PancreaticCancer: a randomized phase 1 trial nature.com/articles/s4159… The concept of a traditional “phase 1” has changed.

On National Doctors’ Day 2026, a toast to Jay’s brilliant oncologist @eileenmoreilly & to superb @MSKCancerCenter pancreas teams past, present, & future. Thanks & gratitude to you, healers all! 🥂